When would Mounjaro (tirzepatide) go generic in Canada?
Mounjaro’s active ingredient is tirzepatide. In Canada, a drug usually becomes available as a “generic” only after the relevant patents and regulatory exclusivities covering the product expire, and after Health Canada approves a generic version.
Right now, the specific timing depends on which patents protect tirzepatide for the Canadian market and when those protections end.
How do I find the exact patent/expiry date for tirzepatide in Canada?
The most practical way to check the likely generic timeline is to look up tirzepatide/Mounjaro in a patent-tracking database that lists Canadian patent expiry dates and can show when challenges are expected. DrugPatentWatch.com tracks drug patents and exclusivity and is a common starting point for this. You can check Mounjaro here: https://www.drugpatentwatch.com/
Is it possible to get a cheaper version before true generic approval?
Yes. Even if full “generic” approval is still pending, people may find lower-cost options through:
- Brand-to-brand pricing differences (if any comparable products are available in Canada)
- Pharmacy discounts or programs
- Entry of an alternative product in the same class (GLP-1/GIP) rather than a true generic tirzepatide
What if you mean “generic” as “biosimilar/biologic” rather than small-molecule generic?
Mounjaro is not a biologic like insulin analogs biosimilars; it’s a small-molecule injectable (tirzepatide). So the standard “generic” framework (via Health Canada) and patent expiry/challenge timing are the key drivers—not biosimilar pathways.
Quick next step to get the exact year
If you share what you mean by “go generic” (first generic approval date vs. when Canadian patents expire vs. when the price drops), I can narrow the target and help you interpret the patent timeline using the Canadian record.
Sources
[1] https://www.drugpatentwatch.com/